共 50 条
- [21] Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial resultsIMMUNOTHERAPY, 2023, 15 (11) : 839 - 851Verschueren, Marjon V.Dijs, TalithaGulikers, Judith L.van Veelen, ArdCroes, SanderHendriks, Lizza E. L.Smit, Adrianus A. J.Bloem, Lourens T.Egberts, Antoine C. G.van de Garde, Ewoudt M. W.Peters, Bas J. M.
- [22] Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian ExperienceSOUTH ASIAN JOURNAL OF CANCER, 2020, 9 (03) : 180 - 182Noronha, VanitaTalreja, Vikas T.Patil, VijayJoshi, AmitMenon, NandiniMahajan, AbhishekJanu, AmitPrabhash, Kumar
- [23] Nivolumab Plus Ipilimumab in Relapsed Stage III Non-Small Cell Lung Cancer After Durvalumab Following ChemoradiotherapyJOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S589 - S589Tokito, T.Mouri, A.Watanabe, S.Nagai, Y.Imai, H.Yamaguchi, O.Saida, Y.Kobayashi, K.Kaira, K.Kagamu, H.
- [24] Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung Cancer ReplyJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07) : 768 - +Ahn, Jin SeokPark, Keunchil
- [25] Concurrent Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer: What Is the Best Regimen?JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) : 532 - U12Eberhardt, Wilfried Ernst Erich
- [26] Use of durvalumab in stage III non-small-cell lung cancer based on eligibility for the PACIFIC studyTHORACIC CANCER, 2023, 14 (06) : 563 - 572Boys, EmmaGao, BoHui, Rinada Silva, InesHau, EricGee, HarrietNagrial, Adnan
- [27] Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER studyLUNG CANCER, 2024, 190Kim, Dong-WanCho, Byoung ChulPachipala, KrishnaKim, Sang-WeWang, Chih-LiangChang, Gee -ChenAhn, Myung-JuAlvarez, RosaChiu, Chao-HuaTrigo, JoseEstival, AnnaKaram, Sana D.O'Brien, CathyGowda, HemaJiang, HaiyiBauman, Julie E.
- [28] Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung CancerNEW ENGLAND JOURNAL OF MEDICINE, 2024,Cheng, YingSpigel, David R.Cho, Byoung ChulLaktionov, Konstantin K.Fang, JianChen, YuanbinZenke, YoshitakaLee, Ki HyeongWang, QimingNavarro, AlejandroBernabe, ReyesBuchmeier, Eva LotteChang, John Wen-ChengShiraishi, YoshimasaGoksu, Sema SezginBadzio, AndrzejShi, AnhuiDaniel, Davey B.Hoa, Nguyen Thi ThaiZemanova, MiladaMann, HelenGowda, HemaJiang, HaiyiSenan, Suresh
- [29] Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case reportIMMUNOTHERAPY, 2020, 12 (06) : 373 - 378Kato, YasuhiroWatanabe, YasutakaYamane, YukiMizutani, HideakiKurimoto, FutoshiSakai, Hiroshi
- [30] Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancerTHORACIC CANCER, 2022, 13 (22) : 3152 - 3161Huang, YiqingZhao, Joseph J.Soon, Yu YangWong, AlvinAminkeng, FolefacAng, YvonneAsokumaran, YugarajahLow, Jia LiLee, MatildaChoo, Joan R. E.Chan, GloriaKee, AdrianTay, Sen HeeGoh, Boon CherSoo, Ross A.